ClinicalTrials.gg
CompletedNCT06089278Updated Nov 10, 2026

A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.

A Phase 2 interventional study of 300mg of TQH2722 injection and 600mg of TQH2722 injection in Sinusitis, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Completed at 36 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Updated Nov 10, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Sinusitis with a site in China — 5 open to participants now, 7 under way, 1 of them phase 3. Sinusitis · China.

Enrollment
2nd of 12
160 · median 79
Started
2023
with 2 others
Phase 2
4 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
1 of 14
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Among the 14 studies in Sinusitis with a site in China, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 2, and was the 9th registered.

Sinusitis

256 studies on the registry are indexed under Sinusitis; 23 are open to participants now.

Browse Sinusitis studies →

Open to participants now

5 of the 14 studies in Sinusitis with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 15 Sinusitis studies recruiting now, 6 (40%) set no upper age limit and 6 (40%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Sinusitis with a site in China, or all of them as a file.
02

Study summary

To evaluate the effectiveness, safety and pharmacokinetics of TQH2722 injection in patients with chronic sinusitis with or without nasal polyps.

03

Conditions studied

  • Sinusitis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75 years old, gender is not limited;
  • Bilateral chronic sinusitis (with or without nasal polyps) that meets the diagnostic criteria of The Chinese Guidelines for the Diagnosis and Treatment of Chronic Sinusitis (2018);
  • Systemic (at least 1 course of prednisone 0.5 to 1 mg/kg/day or equivalent for at least 5 days) within 2 years prior to the screening, but bilateral chronic sinusitis still exist; and/or patients with drug /intolerance to systemic glucocorticoids, and (or) patients who have undergone sinus surgery more than 6 months before the screening;
  • Before the screening, subjects must have used a stable dose of intranasal corticosteroids (INCS) for more than 4 weeks; For participants who used INCS alternatives rather than Mometasone furoate nasal spray (MFNS) prior to screening, participants should be willing to switch to MFNS in the duration of the study;
  • Subjects with asthma started inhaled glucocorticoids at a stable dose at least 4 weeks before the screening and could remain inhaled glucocorticoid doses unchanged throughout the study;
  • Patients in the Run-in period should be willing to conduct diary, daily symptom assessment and maintain a stable dose of MFNS with at least 70% adherence;
  • Be able to read and understand, and be willing to sign ;
  • Participants and their partners agreed to use effective throughout the study period (from the beginning of the screening/run-in period to 3 months after the last dose).
  • Part A only:Bilateral nasal polyp score (NPS) assessed by nasal endoscopy ≥5 at both screening and randomization, with a score of ≥2 in each nostril;
  • Part A only:Nasal congestion score (NCS) ≥2 at screening (daily score) and at randomization (weekly average score);
  • Part A only:The following symptoms have been present continuously for at least 8 weeks prior to screening: ① nasal congestion; ② any other symptom, such as hyposmia/anosmia or rhinorrhea.
  • Part B only:Prior to randomization, participants must have bilateral sinus inflammation on CT scan with a total bilateral LMK score ≥8, and bilateral ethmoid sinus opacification.
  • Part B only: No nasal polyps confirmed by nasal endoscopy at Visit 1 and at randomization.
  • Part B only:Subjects must have had persistent hyposmia for at least 4 consecutive weeks prior to Visit 1.
  • Part B only:At screening, subjects have moderate or severe smell loss (smell loss score ≥2), and the weekly average severity ≥2 at randomization.
  • Part B only:Subjects must have a sTSS (nasal congestion [NC], rhinorrhea, facial pain/pressure) ≥2 at screening (daily score) and at randomization (weekly average score).
  • Part B only:Participants who have had at least one blood routine test within 2 years prior to screening, or at screening, showing blood eosinophils meeting any of the following criteria:

    1. Blood eosinophil count ≥0.25×10⁹/L;
    2. Blood eosinophil percentage ≥6.9% and the subject does not have asthma;
    3. Blood eosinophil percentage ≥3.7% and the subject has asthma.

Exclusion criteria

Exclusion Criteria:

  • Any of the following laboratory abnormalities present at screening or randomization:

    1. (ALT) or aspartate aminotransferase (AST) >2.5 × (ULN);
    2. Total >2 × ULN (except for indirect bilirubin elevation secondary to Gilbert's syndrome);
    3. Creatinine >1.5 × ULN;
  • Any disease that the investigator considers unstable and may affect the patient's safety throughout the study period, or affect or interpretation with the results, or interfere with the patient's ability to complete the entire research process, including but not limited to cardiovascular, gastrointestinal, liver, kidney, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic diseases, psychiatric disorders, or major limb disorders. For example, but not limited to: ischemic heart disease, left ventricular failure, arrhythmia, uncontrolled hypertension, uncontrolled hyperglycemia, cerebrovascular disease, etc.;
  • Patients with active disease(including, but not limited to, Hashimoto's thyroiditis, Graves' disease, inflammatory bowel disease, primary biliary cholangitis, systemic lupus erythematosus, multiple sclerosis and other neuroinflammatory diseases, psoriasis vulgaris, and rheumatoid arthritis);
  • Known or suspected , including but not limited to a history of invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), even if the infection has resolved;
  • Subjects with active malignant tumors or a history of malignant tumors; Patients with basal cell carcinoma, localized squamous cell carcinoma of the skin, or carcinoma in situ of the cervix may be enrolled in this study if at least 12 months have elapsed since the completion of curative treatment prior to Visit 1; patients with other malignant tumors may be enrolled in this study if at least 5 years have elapsed since the completion of curative treatment prior to Visit 1;
  • History of active pulmonary tuberculosis within the 12 months before screening;
  • Active hepatitis during the screening period, or positive surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb) and positive hepatitis B virus (HBV) DNA, or positive virus (HCV) antibody and positive HCV-RNA; or positive for antibodies to (Anti-HIV) or positive for treponemal antibodies (Anti-TP);
  • Diagnosed with helminth parasitic infection within 6 months before the screening period, did not receive standard treatment or the standard treatment was ineffective;
  • Subjects who have received any of the following treatments:

    1. Sinus surgery or sinonasal surgery within 6 months prior to screening (Visit 1);
    2. Treatment with monoclonal antibodies within 8 weeks or 5 half-lives prior to screening, whichever is longer, including but not limited to benralizumab, mepolizumab, omalizumab, reslizumab, dupilumab, and other drugs of the same class (IL-4R inhibitors), etc;
    3. Treatment with immunosuppressive agents within 8 weeks or 5 half-lives prior to screening, whichever is longer, including but not limited to cyclophosphamide, cyclosporine, interferon-γ, azathioprine, methotrexate, mycophenolate mofetil, and tacrolimus, etc;
    4. Use of other non-biologic drugs within 8 weeks or 5 half-lives prior to screening, whichever is longer;
    5. Intravenous immunoglobulin (IVIG) therapy and/or plasmapheresis within 30 days prior to the screening visit (Visit 1);
    6. Subjects who received leukotriene antagonists/modifiers within 4 weeks prior to randomization (subjects on a stable dose of leukotriene modifiers for ≥30 consecutive days prior to randomization may be enrolled);
    7. Initiated allergen immunotherapy within 3 months prior to screening, or planned to initiate such treatment during the study period or to change the treatment dose during the study;
    8. Receipt of within 4 weeks prior to screening, or planned receipt of live attenuated vaccines during the study period;
    9. Use of systemic within 4 weeks prior to screening;
    10. Within 2 weeks prior to screening or during the screening/run-in period, had a chronic active or acute infection requiring systemic treatment with antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungal agents;
  • Patients with combined asthma should be excluded if they have:

    1. (FEV1) ≤ 50% of normal estimates;
    2. Acute exacerbation of asthma within 90 days prior to screening, requiring hospitalization (>24 hours);
    3. used daily doses higher than 1000 mcg of fluticasone or equivalent inhaled corticosteroids (ICS);
  • The subject had concomitant diseases that prevented him/her from completing the screening period assessment or from evaluating the primary efficacy endpoint:

    1. Deviation of the nasal septum causing complete obstruction of at least one nostril;
    2. Acute sinusitis, nasal infection, or upper respiratory tract infection at screening or within 2 weeks prior to screening;
    3. Persistent rhinitis medicamentosa;
    4. Diagnosed with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other ciliary dyskinesia syndromes, or cystic fibrosis;
    5. Radiologically suspected or confirmed fungal rhinosinusitis;
  • Subjects with nasal and benign tumors (e.g., papillomas, hemangiomas, etc.);
  • Subjects who are unable to use MFNS or who are allergic or intolerant to mometasone furoate nasal spray;
  • Subjects with a history of anaphylaxis to any biological agent (other than local injection site reactions);
  • Pregnant or lactating women;
  • Alcoholism, drug addiction and known drug dependence;
  • Have participated in clinical trials of other medical devices within 12 weeks before screening;
  • The subject had poor compliance in the research and could not complete the study as judged by the investigator;
  • In the judgment of the investigator or sponsoring medical reviewer, it is believed that there are any medical or psychiatric symptoms that put the subject at risk, interfere with participation in the study, or interfere with the interpretation of the results of the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    300mg of TQH2722 injection

    TQH2722 injection, 14 days as a treatment cycle.

    Drug: 300mg of TQH2722 injection

  • Experimental
    600mg of TQH2722 injection

    TQH2722 injection, 14 days as a treatment cycle.

    Drug: 600mg of TQH2722 injection

  • Placebo comparator
    TQH2722 injection matching placebo

    TQH2722 injection matching placebo, 14 days as a treatment cycle.

    Drug: TQH2722 injection matching placebo

Interventions

  • Drug300mg of TQH2722 injection

    TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

  • Drug600mg of TQH2722 injection

    TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

  • DrugTQH2722 injection matching placebo

    Placebo without active substance.

06

What researchers measure

Primary outcomes

  1. Changes in the nasal polyp score of subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) from baseline at week 16 in part A

    Changes in nasal polyp score from baseline in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) at week 16 in part A. The total score is 0-8 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  2. Changes in the Lund-Mackay score of sinus CT scans of subjects with chronic rhinosinusitis without nasal polyps (CRSsNP) from baseline at week 16 in part B

    Changes in Lund-Mackay score on sinus CT scan from baseline in subjects with chronic rhinosinusitis without nasal polyps (CRSsNP) at week 16 in part B. The total score is 0-24 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

Secondary outcomes

  1. Changes in Lund-Mackay scores of CT scans of subjects from baseline at week 16 in Part A

    Changes in Lund-Mackay scores of CT scans of subjects from baseline at week 16 in Part A. The total score is 0-24 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  2. Changes in the subjects' modified Lund-Kennedy endoscopic scores from baseline at week 16 in Part A

    Changes in the subjects' modified Lund-Kennedy endoscopic scores from baseline at week 16 in Part A. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  3. Changes in the subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part A

    Changes in the subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part A. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  4. Changes in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part A

    Changes in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part A. The total score is 0-110 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  5. Changes in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline at week 16 in Part A.

    Changes in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline at week 16 in Part A. The total score is 0-40 points, with the lower score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  6. Changes in loss-of-smell score of the subjects from baseline at week 16 in Part A

    Changes in loss-of-smell score of the subjects from baseline at week 16 in Part A. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  7. Changes in nasal congestion score (NCS) of subjects from baseline at week 16in Part A

    Changes in nasal congestion score (NCS) of subjects from baseline at week 16 in Part A. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  8. Changes in nasal discharge/post-nasal drip score of the subjects from baseline at week 16 in Part A

    Changes in nasal discharge/post-nasal drip score of the subjects from baseline at week 16in Part A. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  9. Changes in facial pain/pressure score of the subjects from baseline at week 16 in Part A

    Changes in facial pain/pressure score of the subjects from baseline at week 16 in Part A. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  10. Changes in the visual analogue scale (VAS) score of the subjects from baseline at week 16in Part A

    Changes in the visual analogue scale (VAS) score of the subjects from baseline at week 16 in Part A. The total score is 0-10 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  11. Changes in health-related quality of life (HRQoL) at Week 16 of the subjects from baseline at week 16 in Part A

    Changes in health-related quality of life (HRQoL) at Week 16 of the subjects from baseline at week 16 in Part A. The Health survey short form (SF-36) total score is 0-100 points, with the higher score meaning the higher quality of life.

    Time frame: Up to 16 weeks.

  12. Changes in peak nasal inspiratory flow rate (NPIF) of the subjects from baseline at week 16 in Part A

    Changes in peak nasal inspiratory flow rate (NPIF) of the subjects from baseline at week 16 in Part A

    Time frame: Up to 16 weeks.

  13. Proportion of subjects who received systemic corticosteroids (SCS) rescue therapy or surgical treatment during the 16-week treatment period in Part A

    Proportion of subjects who received systemic corticosteroids (SCS) rescue therapy or surgical treatment during the 16-week treatment period s in Part A.

    Time frame: Up to 16 weeks.

  14. Incidence of adverse events in Part A

    Incidence of adverse events (AES) and serious adverse events (SAEs), as well as abnormal laboratory test indicators in Part A

    Time frame: Up to 24 weeks.

  15. Severity of adverse events in Part A

    Severity of adverse events (AES) and serious adverse events (SAEs), as well as abnormal laboratory test indicators in Part A

    Time frame: Up to 24 weeks.

  16. peak plasma concentration (Cmax)in Part A

    Maximum plasma drug concentration in Part A

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  17. Trough concentration (Cmin) in Part A

    Minimum plasma drug concentration in Part A

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  18. Time to peak concentration (Tmax)in Part A

    The time required to reach peak concentration after administration in Part A

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  19. Area under the plasma concentration-time curve (AUC0-t)in Part A

    The area enclosed by the plasma concentration curve to the timeline in Part A.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  20. Steady-state peak concentration (Css-max) in Part A

    The highest plasma concentration that occurs in steady state in Part A.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  21. Steady-state valley concentration (Css-min) in Part A

    The lowest plasma concentration that occurs in steady state in Part A.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  22. Average steady-state plasma concentration (Css-av) in Part A

    The quotient obtained by dividing the area under the plasma concentration-time curve by the interval time τ during a dose interval when the blood concentration reaches a steady state in Part A.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  23. Steady-state time to peak concentration (Tss-max) in Part A

    The time required to reach peak steady-state concentration after administration in Part A

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  24. Steady-state area under the plasma concentration-time curve (AUCss,0-t) in Part A

    Area under the plasma concentration-time curve in steady state in Part A.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  25. Half-life (t1/2) in Part A

    The time it takes for half the drug to be eliminated from the body in Part A

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  26. Apparent volume of distribution (Vd/F) in Part A

    The ratio of the amount of drug in the body to the concentration in the blood after the drug has reached homeostasis in the body in Part A

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  27. Clearance (CL/F) in Part A

    Per unit time, the volume of drug-containing liquid is completely and effectively removed by the elimination organ in Part A

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  28. Anti-drug antibody (ADA) positive rate of subjects in Part A

    Anti-drug antibody (ADA) positive rate of subjects in Part A

    Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.

  29. Titer of Anti-drug antibody (ADA) of subjects in Part A

    Titer of Anti-drug antibody (ADA) of subjects in Part A

    Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.

  30. Incidence of subjects with neutralizing antibodies (Nab) in Part A

    Incidence of subjects with neutralizing antibodies (Nab) in Part A.

    Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.

  31. Changes in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline at week 16in Part B

    Changes in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline at week 16 in Part B. The total score is 0-40 points, with the lower score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  32. Changes in loss-of-smell score of the subjects from baseline at week 16 in Part B

    Changes in loss-of-smell score of the subjects from baseline at week 16 in Part B. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  33. Changes in the subjects' modified Lund-Kennedy endoscopic scores from baseline at week 16 in Part B

    Changes in the subjects' modified Lund-Kennedy endoscopic scores from baseline at week 16 in Part B. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  34. Changes in the subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part B

    Changes in the subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part B. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  35. Changes in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part B

    Changes in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part B. The total score is 0-110 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  36. Changes in nasal discharge/postnasal drip score of the subjects from baseline at week 16 in Part B

    Changes in nasal discharge/postnasal drip score of the subjects from baseline at week 16 in Part B. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  37. Changes in facial pain/pressure score of the subjects from baseline at week 16 in Part B

    Changes in facial pain/pressure score of the subjects from baseline at week 16 in Part B. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  38. Changes in the visual analogue scale (VAS) of the subjects from baseline at week 16s in Part B

    Changes in the visual analogue scale (VAS) of the subjects from baseline at week 16 in Part B. The total score is 0-10 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  39. Proportion of subjects who received systemic corticosteroids (SCS) rescue therapy or surgical treatment during the 16-week treatment period in Part B

    Proportion of subjects who received systemic corticosteroids (SCS) rescue therapy or surgical treatment during the 16-week treatment period in Part B.

    Time frame: Up to 16 weeks.

  40. Incidence of adverse events in Part B

    Incidence of adverse events (AES) and serious adverse events (SAEs), as well as abnormal laboratory test indicators in Part B.

    Time frame: Up to 24 weeks.

  41. Severity of adverse events in Part B

    Severity of adverse events (AES) and serious adverse events (SAEs), as well as abnormal laboratory test indicators in Part B.

    Time frame: Up to 24 weeks.

  42. Peak plasma concentration in Part B

    Maximum plasma drug concentration in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  43. Trough concentration (Cmin) in Part B

    Minimum plasma drug concentration in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  44. Time to peak concentration (Tmax) in Part B

    The time required to reach peak concentration after administration in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  45. Area under the plasma concentration-time curve (AUC0-t)in Part B

    The area enclosed by the plasma concentration curve to the timeline in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  46. Steady-state peak concentration (Css-max) in Part B

    The highest plasma concentration that occurs in steady state in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  47. Steady-state trough concentration (Css-min) in Part B

    The lowest blood concentration that occurs in steady state in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  48. Average steady-state plasma concentration (Css-av) in Part B

    The quotient obtained by dividing the area under the blood concentration-time curve by the interval time τ during a dose interval when the blood concentration reaches a steady state in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  49. Steady-state time to peak concentration (Tss-max) in Part B

    The time required to reach peak steady-state concentration after administration in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  50. Steady-state area under the plasma concentration-time curve (AUC ss,0-t) in Part B

    Area under the plasma concentration-time curve in steady state in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  51. half-life in Part B

    The time it takes for half the drug to be eliminated from the body in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  52. Apparent volume of distribution (Vd/F) in Part B

    The ratio of the amount of drug in the body to the concentration in the blood after the drug has reached homeostasis in the body in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  53. Clearance (CL/F) in Part B

    Per unit time, the volume of drug-containing liquid is completely and effectively removed by the elimination organ in Part B.

    Time frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.

  54. Anti-drug antibody (ADA) positive rate of subjects in Part B

    Anti-drug antibody (ADA) positive rate of subjects in Part B.

    Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.

  55. Titer of Anti-drug antibody (ADA) of subjects in Part B

    Titer of Anti-drug antibody (ADA) of subjects in Part B.

    Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.

  56. Incidence of subjects with neutralizing antibodies (Nab) in Part B

    Incidence of subjects with neutralizing antibodies (Nab) in Part B.

    Time frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.

  57. Changes in Asthma Control Questionnaire (ACQ-6) score from baseline among subjects with combined asthma in part A

    Change in ACQ-6 score from baseline among subjects with combined asthma in part A. The total score ranges from 0 to 6, with higher scores indicating less well-controlled asthma

    Time frame: Up to 16 weeks.

  58. Change of total Immunoglobulin E (IgE) in peripheral blood from baseline in Part A

    Change of total Immunoglobulin E (IgE) in peripheral blood from baseline in subjects at Week 16 in Part A.

    Time frame: Up to 16 weeks.

  59. Change of Eosinophil count in peripheral blood from baseline in Part A

    Change of Eosinophil count in peripheral blood from baseline in subjects in Part A.

    Time frame: Up to 16 weeks.

  60. Change from baseline in peripheral blood eotaxin-3 (CCL26) concentrations in subjects in Part A

    Change from baseline in peripheral blood eotaxin-3 (CCL26) concentrations in subjects at Week 16 in Part A.

    Time frame: Up to 16 weeks.

  61. Change from baseline in peripheral blood Cystatin-SN (CST1) in subjects in part A

    Change from baseline in peripheral blood Cystatin-SN (CST1) in subjects at Week 16 in part A.

    Time frame: Up to 16 weeks

  62. Change from baseline in Cystatin-SN (CST1) in nasal exfoliated cells in Part A

    Change from baseline in Cystatin-SN (CST1) in nasal exfoliated cells in subjects at Week 16 in Part A.

    Time frame: Up to 16 weeks

  63. Change from baseline in eotaxin-3 (CCL26) in nasal exfoliated cells in Part A

    Change from baseline in eotaxin-3 (CCL26) in nasal exfoliated cells in subjects at Week 16 in Part A

    Time frame: Up to 16 weeks

  64. Change from baseline in Charcot-Leyden crystal protein (CLC) in nasal exfoliated cells in Part A

    Change from baseline in Charcot-Leyden crystal protein (CLC) in nasal exfoliated cells in Part A.

    Time frame: Up to 16 weeks.

  65. Change from baseline inArachidonate 15-lipoxygenase (ALOX15) in nasal exfoliated cells in Part A

    Change from baseline in Arachidonate 15-lipoxygenase (ALOX15) in nasal exfoliated cells in subjects at Week 16 in Part A

    Time frame: Up to 16 weeks.

  66. Change from baseline in cytokines in nasal secretions of Part A

    Changes in cytokines in nasal secretions from baseline at week 16 of Part A.

    Time frame: Up to 16 weeks

  67. Changes in microorganisms in nasal secretions from baseline at week 16 of Part A

    Change from baseline in microbiota in nasal secretions in subjects at Week 16 of Part A.

    Time frame: Up to 16 weeks.

  68. Changes in nasal congestion score (NCS) from baseline at week 16 in Part B

    Change in subjects' Nasal congestion Score (NCS) from baseline at week 16 in Part B. The total score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Up to 16 weeks.

  69. Changes in ACQ-6 scores in subjects with asthma from baseline at week 16 in part B

    Change in ACQ-6 score from baseline among subjects with combined asthma in part B. The total score ranges from 0 to 6, with higher scores indicating less well-controlled asthma.

    Time frame: Up to 16 weeks.

  70. Change of total Immunoglobulin E (IgE) in peripheral blood from baseline in Part B

    Change of total Immunoglobulin E (IgE) in peripheral blood from baseline in subjects at Week 16 in Part B.

    Time frame: Up to 16 weeks

  71. Change of Eosinophil count in peripheral blood from baseline in Part B

    Change of Eosinophil count in peripheral blood from baseline in subjects in Part A

    Time frame: Up to 16 weeks

  72. Change from baseline in peripheral blood eotaxin-3 (CCL26) concentrations in subjects in Part B

    Change from baseline in peripheral blood eotaxin-3 (CCL26) concentrations in subjects at Week 16 in Part B

    Time frame: Up to 16 weeks.

  73. Change from baseline in Cystatin-SN (CST1) in subjects in part B

    Change from baseline in Cystatin-SN (CST1) in subjects at Week 16 in part B

    Time frame: Up to 16 weeks.

  74. Change from baseline in Cystatin-SN (CST1) in nasal exfoliated cells in Part B

    Change from baseline in Cystatin-SN (CST1) in nasal exfoliated cells in subjects at Week 16 in Part B.

    Time frame: Up to 16 weeks.

  75. Change from baseline in eotaxin-3 (CCL26) in nasal exfoliated cells in Part B

    Change from baseline in eotaxin-3 (CCL26) in nasal exfoliated cells in subjects at Week 16 in Part B.

    Time frame: Up to 16 weeks.

  76. Change from baseline in Charcot-Leyden crystal protein (CLC) in nasal exfoliated cells in Part B

    Change from baseline in Charcot-Leyden crystal protein (CLC) in nasal exfoliated cells in subjects at Week 16 in Part B.

    Time frame: Up to 16 weeks.

  77. Change from baseline inArachidonate 15-lipoxygenase (ALOX15) in nasal exfoliated cells in Part B

    Change from baseline in Arachidonate 15-lipoxygenase (ALOX15) in nasal exfoliated cells in subjects at Week 16 in Part B.

    Time frame: Up to 16 weeks.

  78. Change from baseline in cytokines in nasal secretions of Part B

    Changes in cytokines in nasal secretions from baseline at week 16 of Part B.

    Time frame: Up to 16 weeks.

  79. Change from baseline in microbiota in nasal secretions of Part B

    Changes in microorganisms in nasal secretions from baseline at week 16 of Part B.

    Time frame: Up to 16 weeks.

  80. Changes in health-related quality of life (HRQoL) at Week 16 of the subjects from baseline at week 16 in Part B

    Changes in health-related quality of life (HRQoL) at Week 16 of the subjects from baseline at week 16 in Part B. The Health survey short form (SF-36) total score is 0-100 points, with the higher score meaning the higher quality of life.

    Time frame: Up to 16 weeks.

07

Study locations

36 sites
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241000, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100005, China
  • Beijing TongRen Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730000, China
  • Foshan First People's Hospital
    Foshan, Guangdong 528000, China
  • Jieyang People's Hospital
    Jieyang, Guangdong 522000, China
  • The Second People's Hospital of Shenzhen
    Shenzhen, Guangdong 518035, China
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
  • The Affiliated hospital of Guizhou Medical University
    Guiyang, Guizhou 550000, China
  • Cangzhou Central Hospital
    Cangzhou, Hebei 061000, China
  • Hebei Medical University Third Hospital
    Shijiazhuang, Hebei 050000, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
  • Union Hospitalc, Tongji Medical College, Huazhong, University of Science and Technology
    Wuhan, Hubei 430023, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • Loudi Central Hospital
    Changsha, Hunan 417000, China
  • Baotou Central Hospital
    Baotou, Inner Mongolia 014040, China
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 010000, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Jilin Province People's Hospital
    Changchun, Jilin 130012, China
  • The Affiliated Hospital of Yanbian University
    Yanji, Jilin 133002, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • Central Hospital of Shenyang Medical College
    Shenyang, Liaoning 110024, China
  • Shandong Second People's Hospital
    Jinan, Shandong 250022, China
  • Weifang Second People's Hospital
    Weifang, Shandong 261041, China
  • Weihai Central Hospital
    Weihai, Shandong 264400, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
  • Zibo Central Hospital
    Zibo, Shandong 255036, China
  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200000, China
  • First Hospital of Shanxi Medical University
    Taiyuan, Shanxi 30001, China
  • Chengdu Second People's Hospital
    Chengdu, Sichuan 610000, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830011, China
  • Wenling First People's Hospital
    Taizhou, Zhejiang 317599, China
  • Taizhou central hospital
    Taizhou, Zhejiang 318000, China
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Mar 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Oct 18, 2023
StartActual
Dec 28, 2023
Primary completionActual
Mar 30, 2025
CompletionActual
Apr 30, 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Criteria revised in 2 updates
What changed on Oct 22, 2026
Inclusion criteria
  • AddedPart A only:Bilateral nasal polyp score (NPS) assessed by nasal endoscopy ≥5 at both screening and randomization, with a score of ≥2 in each nostril;
  • AddedPart A only:Nasal congestion score (NCS) ≥2 at screening (daily score) and at randomization (weekly average score);
  • AddedPart A only:The following symptoms have been present continuously for at least 8 weeks prior to screening: ① nasal congestion; ② any other symptom, such as hyposmia/anosmia or rhinorrhea.
  • AddedPart B only:Prior to randomization, participants must have bilateral sinus inflammation on CT scan with a total bilateral LMK score ≥8, and bilateral ethmoid sinus opacification.
  • AddedPart B only: No nasal polyps confirmed by nasal endoscopy at Visit 1 and at randomization.
  • AddedPart B only:Subjects must have had persistent hyposmia for at least 4 consecutive weeks prior to Visit 1.
  • AddedPart B only:At screening, subjects have moderate or severe smell loss (smell loss score ≥2), and the weekly average severity ≥2 at randomization.
  • AddedPart B only:Subjects must have a sTSS (nasal congestion [NC], rhinorrhea, facial pain/pressure) ≥2 at screening (daily score) and at randomization (weekly average score).
  • AddedPart B only:Participants who have had at least one blood routine test within 2 years prior to screening, or at screening, showing blood eosinophils meeting any of the following criteria:
  • AddedBlood eosinophil count ≥0.25×10⁹/L;
  • AddedBlood eosinophil percentage ≥6.9% and the subject does not have asthma;
  • AddedBlood eosinophil percentage ≥3.7% and the subject has asthma.
Exclusion criteria
  • AddedAny of the following laboratory abnormalities present at screening or randomization:
  • AddedAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 × upper limit of normal (ULN);
  • AddedTotal bilirubin >2 × ULN (except for indirect bilirubin elevation secondary to Gilbert's syndrome);
  • AddedCreatinine >1.5 × ULN;
  • RemovedPatients with active autoimmune disease;
  • RemovedKnown or suspected immunosuppressed, including but not limited to invasive opportunistic infections
  • RemovedSubjects with active malignant tumors or a history of malignant tumors;
  • AddedPatients with active autoimmune disease(including, but not limited to, Hashimoto's thyroiditis, Graves' disease, inflammatory bowel disease, primary biliary cholangitis, systemic lupus erythematosus, multiple sclerosis and other neuroinflammatory diseases, psoriasis vulgaris, and rheumatoid arthritis);
  • AddedKnown or suspected immunosuppression, including but not limited to a history of invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), even if the infection has resolved;
  • AddedSubjects with active malignant tumors or a history of malignant tumors; Patients with basal cell carcinoma, localized squamous cell carcinoma of the skin, or carcinoma in situ of the cervix may be enrolled in this study if at least 12 months have elapsed since the completion of curative treatment prior to Visit 1; patients with other malignant tumors may be enrolled in this study if at least 5 years have elapsed since the completion of curative treatment prior to Visit 1;
  • AddedSubjects who have received any of the following treatments:
  • AddedSinus surgery or sinonasal surgery within 6 months prior to screening (Visit 1);
  • AddedTreatment with monoclonal antibodies within 8 weeks or 5 half-lives prior to screening, whichever is longer, including but not limited to benralizumab, mepolizumab, omalizumab, reslizumab, dupilumab, and other drugs of the same class (IL-4R inhibitors), etc;
  • AddedTreatment with immunosuppressive agents within 8 weeks or 5 half-lives prior to screening, whichever is longer, including but not limited to cyclophosphamide, cyclosporine, interferon-γ, azathioprine, methotrexate, mycophenolate mofetil, and tacrolimus, etc;
  • AddedUse of other non-biologic investigational drugs within 8 weeks or 5 half-lives prior to screening, whichever is longer;
  • AddedIntravenous immunoglobulin (IVIG) therapy and/or plasmapheresis within 30 days prior to the screening visit (Visit 1);
  • AddedSubjects who received leukotriene antagonists/modifiers within 4 weeks prior to randomization (subjects on a stable dose of leukotriene modifiers for ≥30 consecutive days prior to randomization may be enrolled);
  • AddedInitiated allergen immunotherapy within 3 months prior to screening, or planned to initiate such treatment during the study period or to change the treatment dose during the study;
  • AddedReceipt of live attenuated vaccines within 4 weeks prior to screening, or planned receipt of live attenuated vaccines during the study period;
  • AddedUse of systemic corticosteroids within 4 weeks prior to screening;
  • AddedWithin 2 weeks prior to screening or during the screening/run-in period, had a chronic active or acute infection requiring systemic treatment with antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungal agents;
  • EditedForced expiratory volume in the first second (FEV1) ≤ 50% of normal estimates, or;
  • EditedAcute exacerbation of asthma within 90 days prior to screening, requiring hospitalization (>24 hours), or;
  • AddedDeviation of the nasal septum causing complete obstruction of at least one nostril;
  • AddedAcute sinusitis, nasal infection, or upper respiratory tract infection at screening or within 2 weeks prior to screening;
  • AddedPersistent rhinitis medicamentosa;
  • AddedDiagnosed with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other ciliary dyskinesia syndromes, or cystic fibrosis;
  • AddedRadiologically suspected or confirmed fungal rhinosinusitis;
What changed on Nov 10, 2026
Inclusion criteria
  • EditedSystemic corticosteroids (at least 1 course of prednisone 0.5 to 1 mg/kg/day or equivalent for at least 5 days) within 2 years prior to the screening, but bilateral chronic sinusitis still exist; and/or patients with drug contraindications/intolerance to systemic glucocorticoids, and (or) patients who have undergone sinus surgery withinmore than 6 months before the screening;
across 2 updates, Oct 22, 2026 – Nov 10, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 22, 2026
  • EditedChanges in nasal polyp score from baseline in Partsubjects with chronic rhinosinusitis with nasal polyps (CRSwNP) at week 16 in part ATime frame: Up to 16 weeks.
  • ChangedBefore Changes in sinus CT scan Lund Mackay score in Part BNow Changes in Lund-Mackay score on sinus CT scan from baseline in subjects with chronic rhinosinusitis without nasal polyps (CRSsNP) at week 16 in part BTime frame: Up to 16 weeks.
What changed on Nov 10, 2026
  • EditedChanges in the nasal polyp score from baseline inof subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) from baseline at week 16 in part ATime frame: Up to 16 weeks.
  • EditedChanges in the Lund-Mackay score onof sinus CT scan from baseline inscans of subjects with chronic rhinosinusitis without nasal polyps (CRSsNP) from baseline at week 16 in part BTime frame: Up to 16 weeks.
across 2 updates, Oct 22, 2026 – Nov 10, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 22, 2026
  • EditedChanges in the Lund-Kennedy score by nasal endoscopy in Part ATime frame: Up to 16 weeks.
  • EditedChanges in University of Pennsylvania Smell Identification Test (UPSIT) in Part A.Time frame: Up to 16 weeks.
  • EditedChanges in Nasal Total Symptom Score (sTSS) in Part ATime frame: Up to 16 weeks.
  • EditedChanges in the Anosmia score in Part A.Time frame: Up to 16 weeks.
  • EditedChanges in nasal congestion score (NCS) in Part A.Time frame: Up to 16 weeks.
  • EditedChanges in nasal/post-nasal discharge scores in Part ATime frame: Up to 16 weeks.
  • EditedChanges in facial pain/pressure scores in Part ATime frame: Up to 16 weeks.
  • EditedChanges in the Visual analogue Scale (VAS) of sinusitis in Part ATime frame: Up to 16 weeks.
  • EditedSubjects' Health-related Quality of Life (HRQoL) questionnaire in Part ATime frame: Up to 16 weeks.
  • EditedChanges in nasal peak inspiratory flow rate (NPIF) in Part ATime frame: Up to 16 weeks.
  • EditedSystemic glucocorticoid (SCS) remedial or surgical treatment rate in Part ATime frame: Up to 16 weeks.
  • EditedIncidence of adverse events in Part ATime frame: Up to 24 weeks.
  • EditedSeverity of adverse events in Part ATime frame: Up to 24 weeks.
  • EditedPeak concentration (Cmax) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedTrough concentration (Cmin) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedPeak time (Tmax) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedArea under blood concentration-time curve (AUC0-t) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedSteady-state peak concentration (Css-max) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedSteady-state valley concentration (Css-min) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedMean steady-state blood concentration (Css-av) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedSteady-state peak time (Tss-max) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedArea under steady state blood concentration-time curve (AUC ss,0-t) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedElimination half-life in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedApparent volume of distribution (Vd/F) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedClearance rate (CL/F) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • AddedChanges in 22-item Sino-Nasal Outcome Test (SNOT-22) in Part A.Time frame: Up to 16 weeks.
  • AddedAnti-drug antibody (ADA) positive rate of subjects in Part ATime frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
  • AddedTiter of Anti-drug antibody (ADA) of subjects in Part ATime frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
  • AddedIncidence of subjects with neutralizing antibodies (Nab) in Part ATime frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
  • AddedChanges in University of Pennsylvania Smell Identification Test (UPSIT) in Part B.Time frame: Up to 16 weeks.
  • …and 48 more, on the record history on ClinicalTrials.gov ↗
What changed on Nov 10, 2026
  • EditedChanges in the subjects' modified Lund-Kennedy score by nasal endoscopyendoscopic scores from baseline at week 16 in Part ATime frame: Up to 16 weeks.
  • EditedChanges in Nasal Total Symptom Scorethe subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part ATime frame: Up to 16 weeks.
  • EditedChanges in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part A.Time frame: Up to 16 weeks.
  • EditedChanges in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline at week 16 in Part A.Time frame: Up to 16 weeks.
  • EditedChanges in nasal congestion score (NCS) inof subjects from baseline at week 16in Part A.Time frame: Up to 16 weeks.
  • EditedChanges in nasal discharge/post-nasal discharge scoresdrip score of the subjects from baseline at week 16 in Part ATime frame: Up to 16 weeks.
  • EditedChanges in facial pain/pressure scoresscore of the subjects from baseline at week 16 in Part ATime frame: Up to 16 weeks.
  • EditedChanges in the Visualvisual analogue Scalescale (VAS) score of sinusitis inthe subjects from baseline at week 16in Part ATime frame: Up to 16 weeks.
  • EditedSubjects' HealthChanges in health-related Qualityquality of Lifelife (HRQoL) questionnaireat Week 16 of the subjects from baseline at week 16 in Part ATime frame: Up to 16 weeks.
  • EditedChanges in peak nasal peak inspiratory flow rate (NPIF) of the subjects from baseline at week 16 in Part ATime frame: Up to 16 weeks.
  • EditedSystemic glucocorticoidProportion of subjects who received systemic corticosteroids (SCS) remedialrescue therapy or surgical treatment rateduring the 16-week treatment period in Part ATime frame: Up to 16 weeks.
  • EditedPeakpeak plasma concentration (Cmax) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedPeak timeTime to peak concentration (Tmax) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedArea under bloodthe plasma concentration-time curve (AUC0-t) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedMeanAverage steady-state bloodplasma concentration (Css-av) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedSteady-state time to peak timeconcentration (Tss-max) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedAreaSteady-state area under steady state bloodthe plasma concentration-time curve (AUC ssAUCss,0-t) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedElimination halfHalf-life (t1/2) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedClearance rate (CL/F) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedChanges in the University of Pennsylvania Smell Identification Test (UPSIT) infrom baseline at week 16in Part B.Time frame: Up to 16 weeks.
  • EditedChanges in the subjects' modified Lund-Kennedy score by nasal endoscopyendoscopic scores from baseline at week 16 in Part BTime frame: Up to 16 weeks.
  • EditedChanges in Nasal Total Symptom Scorethe subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part BTime frame: Up to 16 weeks.
  • EditedChanges in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part B.Time frame: Up to 16 weeks.
  • EditedChanges in facial pain/pressure scoresscore of the subjects from baseline at week 16 in Part BTime frame: Up to 16 weeks.
  • EditedChanges in the Visualvisual analogue Scalescale (VAS) of sinusitisthe subjects from baseline at week 16s in Part BTime frame: Up to 16 weeks.
  • EditedSystemic glucocorticoidProportion of subjects who received systemic corticosteroids (SCS) remedialrescue therapy or surgical treatment rateduring the 16-week treatment period in Part BTime frame: Up to 16 weeks.
  • EditedPeak plasma concentration (Cmax) in Part BTime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedPeak timeTime to peak concentration (Tmax) in Part BTime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedArea under bloodthe plasma concentration-time curve (AUC0-t) in Part BTime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • EditedSteady-state valleytrough concentration (Css-min) in Part BTime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
  • …and 26 more, on the record history on ClinicalTrials.gov ↗
across 2 updates, Oct 22, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedSystemic corticosteroids (at least 1 course of prednisone 0.5 to 1 mg/kg/day or equivalent for at least 5 days) within 2 years prior to the screening, but bilateral chronic sinusitis still exist; and/or patients with drug contraindications/intolerance to systemic glucocorticoids, and (or) patients who have undergone sinus surgery withinmore than 6 months before the screening;
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChanges in the nasal polyp score from baseline inof subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) from baseline at week 16 in part ATime frame: Up to 16 weeks.
    • EditedChanges in the Lund-Mackay score onof sinus CT scan from baseline inscans of subjects with chronic rhinosinusitis without nasal polyps (CRSsNP) from baseline at week 16 in part BTime frame: Up to 16 weeks.
    Secondary outcomes 30 edited, 26 more
    What changed in the outcomes
    • EditedChanges in the subjects' modified Lund-Kennedy score by nasal endoscopyendoscopic scores from baseline at week 16 in Part ATime frame: Up to 16 weeks.
    • EditedChanges in Nasal Total Symptom Scorethe subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part ATime frame: Up to 16 weeks.
    • EditedChanges in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part A.Time frame: Up to 16 weeks.
    • EditedChanges in the University of Pennsylvania Smell Identification Test (UPSIT) from baseline at week 16 in Part A.Time frame: Up to 16 weeks.
    • EditedChanges in nasal congestion score (NCS) inof subjects from baseline at week 16in Part A.Time frame: Up to 16 weeks.
    • EditedChanges in nasal discharge/post-nasal discharge scoresdrip score of the subjects from baseline at week 16 in Part ATime frame: Up to 16 weeks.
    • EditedChanges in facial pain/pressure scoresscore of the subjects from baseline at week 16 in Part ATime frame: Up to 16 weeks.
    • EditedChanges in the Visualvisual analogue Scalescale (VAS) score of sinusitis inthe subjects from baseline at week 16in Part ATime frame: Up to 16 weeks.
    • EditedSubjects' HealthChanges in health-related Qualityquality of Lifelife (HRQoL) questionnaireat Week 16 of the subjects from baseline at week 16 in Part ATime frame: Up to 16 weeks.
    • EditedChanges in peak nasal peak inspiratory flow rate (NPIF) of the subjects from baseline at week 16 in Part ATime frame: Up to 16 weeks.
    • EditedSystemic glucocorticoidProportion of subjects who received systemic corticosteroids (SCS) remedialrescue therapy or surgical treatment rateduring the 16-week treatment period in Part ATime frame: Up to 16 weeks.
    • EditedPeakpeak plasma concentration (Cmax) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedPeak timeTime to peak concentration (Tmax) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedArea under bloodthe plasma concentration-time curve (AUC0-t) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedMeanAverage steady-state bloodplasma concentration (Css-av) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedSteady-state time to peak timeconcentration (Tss-max) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedAreaSteady-state area under steady state bloodthe plasma concentration-time curve (AUC ssAUCss,0-t) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedElimination halfHalf-life (t1/2) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedClearance rate (CL/F) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedChanges in the University of Pennsylvania Smell Identification Test (UPSIT) infrom baseline at week 16in Part B.Time frame: Up to 16 weeks.
    • EditedChanges in the subjects' modified Lund-Kennedy score by nasal endoscopyendoscopic scores from baseline at week 16 in Part BTime frame: Up to 16 weeks.
    • EditedChanges in Nasal Total Symptom Scorethe subjects' sinus total symptom score (sTSS) from baseline at week 16 in Part BTime frame: Up to 16 weeks.
    • EditedChanges in the 22-item Sino-Nasal Outcome Test (SNOT-22) from baseline at week 16 in Part B.Time frame: Up to 16 weeks.
    • EditedChanges in facial pain/pressure scoresscore of the subjects from baseline at week 16 in Part BTime frame: Up to 16 weeks.
    • EditedChanges in the Visualvisual analogue Scalescale (VAS) of sinusitisthe subjects from baseline at week 16s in Part BTime frame: Up to 16 weeks.
    • EditedSystemic glucocorticoidProportion of subjects who received systemic corticosteroids (SCS) remedialrescue therapy or surgical treatment rateduring the 16-week treatment period in Part BTime frame: Up to 16 weeks.
    • EditedPeak plasma concentration (Cmax) in Part BTime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedPeak timeTime to peak concentration (Tmax) in Part BTime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedArea under bloodthe plasma concentration-time curve (AUC0-t) in Part BTime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedSteady-state valleytrough concentration (Css-min) in Part BTime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • …and 26 more, on the record history on ClinicalTrials.gov ↗
    + 1 other change: verification date
  2. Oct 22, 2026
    Eligibility 12 inclusion criteria added; 2 exclusion criteria edited, 23 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • AddedPart A only:Bilateral nasal polyp score (NPS) assessed by nasal endoscopy ≥5 at both screening and randomization, with a score of ≥2 in each nostril;
    • AddedPart A only:Nasal congestion score (NCS) ≥2 at screening (daily score) and at randomization (weekly average score);
    • AddedPart A only:The following symptoms have been present continuously for at least 8 weeks prior to screening: ① nasal congestion; ② any other symptom, such as hyposmia/anosmia or rhinorrhea.
    • AddedPart B only:Prior to randomization, participants must have bilateral sinus inflammation on CT scan with a total bilateral LMK score ≥8, and bilateral ethmoid sinus opacification.
    • AddedPart B only: No nasal polyps confirmed by nasal endoscopy at Visit 1 and at randomization.
    • AddedPart B only:Subjects must have had persistent hyposmia for at least 4 consecutive weeks prior to Visit 1.
    • AddedPart B only:At screening, subjects have moderate or severe smell loss (smell loss score ≥2), and the weekly average severity ≥2 at randomization.
    • AddedPart B only:Subjects must have a sTSS (nasal congestion [NC], rhinorrhea, facial pain/pressure) ≥2 at screening (daily score) and at randomization (weekly average score).
    • AddedPart B only:Participants who have had at least one blood routine test within 2 years prior to screening, or at screening, showing blood eosinophils meeting any of the following criteria:
    • AddedBlood eosinophil count ≥0.25×10⁹/L;
    • AddedBlood eosinophil percentage ≥6.9% and the subject does not have asthma;
    • AddedBlood eosinophil percentage ≥3.7% and the subject has asthma.
    Exclusion criteria
    • AddedAny of the following laboratory abnormalities present at screening or randomization:
    • AddedAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 × upper limit of normal (ULN);
    • AddedTotal bilirubin >2 × ULN (except for indirect bilirubin elevation secondary to Gilbert's syndrome);
    • AddedCreatinine >1.5 × ULN;
    • RemovedPatients with active autoimmune disease;
    • RemovedKnown or suspected immunosuppressed, including but not limited to invasive opportunistic infections
    • RemovedSubjects with active malignant tumors or a history of malignant tumors;
    • AddedPatients with active autoimmune disease(including, but not limited to, Hashimoto's thyroiditis, Graves' disease, inflammatory bowel disease, primary biliary cholangitis, systemic lupus erythematosus, multiple sclerosis and other neuroinflammatory diseases, psoriasis vulgaris, and rheumatoid arthritis);
    • AddedKnown or suspected immunosuppression, including but not limited to a history of invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), even if the infection has resolved;
    • AddedSubjects with active malignant tumors or a history of malignant tumors; Patients with basal cell carcinoma, localized squamous cell carcinoma of the skin, or carcinoma in situ of the cervix may be enrolled in this study if at least 12 months have elapsed since the completion of curative treatment prior to Visit 1; patients with other malignant tumors may be enrolled in this study if at least 5 years have elapsed since the completion of curative treatment prior to Visit 1;
    • AddedSubjects who have received any of the following treatments:
    • AddedSinus surgery or sinonasal surgery within 6 months prior to screening (Visit 1);
    • AddedTreatment with monoclonal antibodies within 8 weeks or 5 half-lives prior to screening, whichever is longer, including but not limited to benralizumab, mepolizumab, omalizumab, reslizumab, dupilumab, and other drugs of the same class (IL-4R inhibitors), etc;
    • AddedTreatment with immunosuppressive agents within 8 weeks or 5 half-lives prior to screening, whichever is longer, including but not limited to cyclophosphamide, cyclosporine, interferon-γ, azathioprine, methotrexate, mycophenolate mofetil, and tacrolimus, etc;
    • AddedUse of other non-biologic investigational drugs within 8 weeks or 5 half-lives prior to screening, whichever is longer;
    • AddedIntravenous immunoglobulin (IVIG) therapy and/or plasmapheresis within 30 days prior to the screening visit (Visit 1);
    • AddedSubjects who received leukotriene antagonists/modifiers within 4 weeks prior to randomization (subjects on a stable dose of leukotriene modifiers for ≥30 consecutive days prior to randomization may be enrolled);
    • AddedInitiated allergen immunotherapy within 3 months prior to screening, or planned to initiate such treatment during the study period or to change the treatment dose during the study;
    • AddedReceipt of live attenuated vaccines within 4 weeks prior to screening, or planned receipt of live attenuated vaccines during the study period;
    • AddedUse of systemic corticosteroids within 4 weeks prior to screening;
    • AddedWithin 2 weeks prior to screening or during the screening/run-in period, had a chronic active or acute infection requiring systemic treatment with antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungal agents;
    • EditedForced expiratory volume in the first second (FEV1) ≤ 50% of normal estimates, or;
    • EditedAcute exacerbation of asthma within 90 days prior to screening, requiring hospitalization (>24 hours), or;
    • AddedDeviation of the nasal septum causing complete obstruction of at least one nostril;
    • AddedAcute sinusitis, nasal infection, or upper respiratory tract infection at screening or within 2 weeks prior to screening;
    • AddedPersistent rhinitis medicamentosa;
    • AddedDiagnosed with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other ciliary dyskinesia syndromes, or cystic fibrosis;
    • AddedRadiologically suspected or confirmed fungal rhinosinusitis;
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChanges in nasal polyp score from baseline in Partsubjects with chronic rhinosinusitis with nasal polyps (CRSwNP) at week 16 in part ATime frame: Up to 16 weeks.
    • ChangedBefore Changes in sinus CT scan Lund Mackay score in Part BNow Changes in Lund-Mackay score on sinus CT scan from baseline in subjects with chronic rhinosinusitis without nasal polyps (CRSsNP) at week 16 in part BTime frame: Up to 16 weeks.
    Secondary outcomes 25 edited, 5 added, 48 more
    What changed in the outcomes
    • EditedChanges in the Lund-Kennedy score by nasal endoscopy in Part ATime frame: Up to 16 weeks.
    • EditedChanges in University of Pennsylvania Smell Identification Test (UPSIT) in Part A.Time frame: Up to 16 weeks.
    • EditedChanges in Nasal Total Symptom Score (sTSS) in Part ATime frame: Up to 16 weeks.
    • EditedChanges in the Anosmia score in Part A.Time frame: Up to 16 weeks.
    • EditedChanges in nasal congestion score (NCS) in Part A.Time frame: Up to 16 weeks.
    • EditedChanges in nasal/post-nasal discharge scores in Part ATime frame: Up to 16 weeks.
    • EditedChanges in facial pain/pressure scores in Part ATime frame: Up to 16 weeks.
    • EditedChanges in the Visual analogue Scale (VAS) of sinusitis in Part ATime frame: Up to 16 weeks.
    • EditedSubjects' Health-related Quality of Life (HRQoL) questionnaire in Part ATime frame: Up to 16 weeks.
    • EditedChanges in nasal peak inspiratory flow rate (NPIF) in Part ATime frame: Up to 16 weeks.
    • EditedSystemic glucocorticoid (SCS) remedial or surgical treatment rate in Part ATime frame: Up to 16 weeks.
    • EditedIncidence of adverse events in Part ATime frame: Up to 24 weeks.
    • EditedSeverity of adverse events in Part ATime frame: Up to 24 weeks.
    • EditedPeak concentration (Cmax) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedTrough concentration (Cmin) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedPeak time (Tmax) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedArea under blood concentration-time curve (AUC0-t) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedSteady-state peak concentration (Css-max) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedSteady-state valley concentration (Css-min) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedMean steady-state blood concentration (Css-av) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedSteady-state peak time (Tss-max) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedArea under steady state blood concentration-time curve (AUC ss,0-t) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedElimination half-life in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedApparent volume of distribution (Vd/F) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • EditedClearance rate (CL/F) in Part ATime frame: Within 1 hour before and 1, 4, 8, 12, 24, 72, 168 hours after the first dose; Within 1 hour before the 2nd, 3rd, and 6th doses; Within 1 hour before and 1, 4, 8, 12, 24, 48, 72, 168, 336, 672, 840 hours after the last dose.
    • AddedChanges in 22-item Sino-Nasal Outcome Test (SNOT-22) in Part A.Time frame: Up to 16 weeks.
    • AddedAnti-drug antibody (ADA) positive rate of subjects in Part ATime frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
    • AddedTiter of Anti-drug antibody (ADA) of subjects in Part ATime frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
    • AddedIncidence of subjects with neutralizing antibodies (Nab) in Part ATime frame: Within 1 hour before the first dose; 336 hours after the last dose; 168 days after the first dose.
    • AddedChanges in University of Pennsylvania Smell Identification Test (UPSIT) in Part B.Time frame: Up to 16 weeks.
    • …and 48 more, on the record history on ClinicalTrials.gov ↗
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06089278
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Dec 28, 2023
Primary completion
Mar 30, 2025
Completion
Apr 30, 2025
Last update
Nov 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion